Medtronic launches new Azure pacemakers in US

Medtronic has announced the US market launch of its new portfolio of Azure pacemakers with BlueSync technology.

The next-generation devices have received US Food and Drug Administration approval and are being made available in both single-chamber and dual-chamber models, offering improved longevity among other benefits.

Both the Azure XT MRI and Azure S MRI models are designed to last around 13.7 years, or 27 percent longer than their predecessors, meaning patients will require fewer device replacements. They also allow patients to safely receive MRI scans.

Their BlueSync technology enables automatic, secure wireless remote monitoring via the Medtronic CareLink Network, providing automated alerts of clinically relevant patient events for review by clinicians.

Meanwhile, the Azure XT model features the Medtronic Reactive atrial-based antitachycardia pacing algorithm, which has been shown to slow the progression of atrial fibrillation in patients with implanted cardiac devices.

Dr John Liddicoat, senior vice-president of Medtronic's cardiac rhythm and heart failure business, said: "With the approval of Azure, clinicians managing patients with bradycardia now have pacemakers with improved longevity, and better ability to detect and reduce atrial fibrillation."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.